AMPLIFIED Phase 2b Success and Proven Efficacy in Proteinuria Reduction

Vertex Pharmaceuticals (VRTX) has demonstrated statistically significant therapeutic efficacy in the Phase 2b trial (AMPLIFIED study) of its developing first-in-class oral drug, inaxaplin (VX-147), for APOL1-mediated kidney disease (AMKD). The Phase 2b trial was conducted over 13 weeks involving 22 patients with moderate proteinuria and 17 patients with AMKD accompanied by Type 2 Diabetes. In the measurement of the primary endpoint, the urinary albumin-to-creatinine ratio (UACR), a marked reduction in proteinuria of 42.7% from baseline was observed in the moderate proteinuria cohort, and a reduction rate of 17.3% was seen in the subgroup of patients with diabetes. The secondary endpoint, Urinary Protein-to-Creatinine Ratio (UPCR), also confirmed consistent glomerular filtration barrier protection with reductions of 44.7% and 25.4%, respectively.

Laying the Foundation for Indication Expansion Beyond Pivotal Trials

These data provide a decisive turning point to significantly expand the indication beyond the target population currently enrolled in the ongoing pivotal global Phase 2/3 trial (AMPLITUDE study). The existing AMPLITUDE trial had completed enrollment by strictly selecting a typical patient group with severe proteinuria but no complications. In contrast, the AMPLIFIED trial holds great clinical significance as it broadened the target range to include patients with mild proteinuria and those with diabetes complications, which are much more commonly observed in clinical settings. Chief Marketing Officer Carmen Bozic described the efficacy in patients with moderate proteinuria as highly encouraging and stated that the company would discuss label expansion through discussions with regulatory authorities.

Moving Beyond Cystic Fibrosis Monopoly and Diversifying the Kidney Portfolio

Vertex has been actively cultivating the kidney disease sector as its next-generation growth engine to reduce dependence on its Cystic Fibrosis (CF) treatment portfolio, which generates billions of dollars in annual revenue. The APOL1 genetic mutation is a fatal genetic variant that rapidly progresses chronic kidney disease and end-stage renal disease (ESRD) in Black and African-descendant populations; inaxaplin is the world's first targeted molecular drug that directly inhibits the APOL1 channel that induces cell death. Through the clinical success of its next-generation kidney pipeline, Vertex is actively transforming itself from a biotech specializing in rare genetic diseases into a leading player in chronic kidney disease therapeutics.

Addressable Market Surpasses 250,000 and Accelerated Approval Roadmap

According to Vertex Investor Relations (IR), the number of AMKD patients in the US and Europe targeted by the existing AMPLITUDE trial was approximately 150,000. However, if these two cohorts are included in the final prescribing label, an additional 100,000 patients would be added, expanding the total addressable patient population to 250,000. Wall Street has long regarded inaxaplin’s peak annual sales as a blockbuster exceeding $1 billion, and this indication expansion provides strong grounds for further upwardly adjusting the commercial sales ceiling. The company plans to release pre-planned interim analysis data from the completed AMPLITUDE trial early next year and intends to initiate an application for FDA Accelerated Approval based on this interim data.